Australia's most trusted
source of pharma news
Saturday, 15 March 2025
Posted 13 March 2025 AM
Ensuring chronic kidney disease (CKD) patients have earlier and faster access to treatments is at the top of AstraZeneca’s priority list with the company’s Business Unit Director for Cardiovascular Renal and Metabolism, Cecelia Bagley, spearheading the push for policy reform in Australia.
In recognition of World Kidney Disease Day, Bagley spoke to Pharma in Focus about the urgent need to prioritise CKD as a public health priority.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.